Low-Density Lipoprotein Oxidizability and the Alteration of Its Fatty Acid Content in Renal Transplant Recipients Treated With Cyclosporine/Tacrolimus

Bakar, Filiz; Keven, Kenan; Doḡru, Bilgehan; Aktan, Fügen; Ertürk, Şehsuvar; Tüzüner, Acar; Erbay, Bülent; Nebioğlu, Serpil

doi:10.1016/j.transproceed.2009.01.091

Cited by 7 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In studies performed by Ghanem et al and Sutherland et al it was found that susceptibility to in vitro oxidation of LDL was higher in CyA treated patients than in healthy subjects 22,23 . Similar results were published by Cofan et al 24 and Bakar et al 25 . These authors showed that treatment with Tac and CyA congenerous increases susceptibility of LDL to in vitro oxidation in comparison with healthy subjects 24,25 .…”

Section: Discussionsupporting

confidence: 91%

“…Similar results were published by Cofan et al 24 and Bakar et al 25 . These authors showed that treatment with Tac and CyA congenerous increases susceptibility of LDL to in vitro oxidation in comparison with healthy subjects 24,25 . On the other hand, it was found that LDL of Tac-treated patients are less susceptible to oxidation than LDL of CyA-treated patients 26 .…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

In vivo oxidized low-density lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study comparing cyclosporine a and tacrolimus based regiments

Zadrazil¹,

Horák²,

Štrebl³

et al. 2012

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aims.Restoration of renal function after kidney transplantation (KT) is expected to improve oxidative stress (OS). However, little is known about the influence of calcineurin inhibitors on oxidized low-density lipoproteins (ox-LDL) after KT. The aim of this study was to evaluate ox-LDLs and related markers of OS, advanced oxidation protein products (AOPP) and total antioxidant status (TAS) in patients after KT on either cyclosporin A (CyA) or tacrolimus (Tac) treatment.Methods. This was a prospective, randomized, single-center 12 month study evaluating time-dependent changes in biomarkers of OS before and after KT. Twenty nine patients (mean age 54.4 ± 11.1; 55% male and 45% female) were treated with CyA (Group A) and twenty four patients (mean age 52.9 ± 9.9; 75% male and 25% female) were treated with Tac (Group B). The ox-LDL, AOPP, TAS, lipid metabolism parameters, creatinine and glomerular filtration were assessed on day 1 before KT and on days 1 and 7, and in months 1, 3, 6 and 12 after KT. Results. Over the 12 months, the ox-LDL for group A changed from 69.2±32.9 to 65.1±17.1 U/L (P=0.665), while AOPP significantly decreased from 233.0±159.6 to 156.5±90.1 μmol/L (P=0.025) and TAS from 1.87±0.31 to 1.68±0.20 mmol/L (P=0.030). For group B the ox-LDL changed from 62.9±29.7 to ± 61.4±14.6 U/L (P=0.168) and TAS from 1.87±0.51 to 1.68±0.20 mmol/L (P=0.168), while AOPP significantly decreased from 180.5±90.0 to 123.9±37.7 μmol/L (P=0.019). Conclusion. AOPP is more sensitive than ox-LDL for assessing OS after KT. TAS values appear to be insufficiently sensitive for monitoring OS in patients after KT.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

In vivo oxidized low-density lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study comparing cyclosporine a and tacrolimus based regiments

Zadrazil¹,

Horák²,

Štrebl³

et al. 2012

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…CNIs and mTORi have a well‐known impact on lipid metabolism with CsA enhancing dyslipidemia to a higher extent than TAC . Our data confirm this finding for all three lipid parameters (Tables and ).…”

Section: Discussionsupporting

confidence: 87%

Dyslipidemia after pediatric renal transplantation—The impact of immunosuppressive regimens

Habbig

Volland

Krupka

et al. 2017

Pediatric Transplantation

View full text Add to dashboard Cite

Dyslipidemia contributes to cardiovascular morbidity and mortality in pediatric transplant recipients. Data on prevalence and risk factors in pediatric cohorts are, however, scarce. We therefore determined the prevalence of dyslipidemia in 386 pediatric renal transplant recipients enrolled in the CERTAIN registry. Data were obtained before and during the first year after RTx to analyze possible non-modifiable and modifiable risk factors. The prevalence of dyslipidemia was 95% before engraftment and 88% at 1 year post-transplant. Low estimated glomerular filtration rate at 1 year post-transplant was associated with elevated serum triglyceride levels. The use of TAC and of MPA was associated with significantly lower concentrations of all lipid parameters compared to regimens containing CsA and mTORi. Immunosuppressive regimens consisting of CsA, MPA, and steroids as well as of CsA, mTORi, and steroids were associated with a three- and 25-fold (P<.001) increased risk of having more than one pathologic lipid parameter as compared to the use of TAC, MPA, and steroids. Thus, amelioration of the cardiovascular risk profile after pediatric RTx may be attained by adaption of the immunosuppressive regimen according to the individual risk profile.

show abstract

“…On the other hand, compared with CsA, TAC produces less lipid disturbances. Indeed a switch to TAC from a CsA-based regimen is associated with resolution of hyperlipidemia [Bakar et al 2009]. …”

Section: And Dyslipidemiamentioning

confidence: 99%

Metabolic consequences of modern immunosuppressive agents in solid organ transplantation

Bamgbola

2016

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Among other factors, sophistication of immunosuppressive (IS) regimen accounts for the remarkable success attained in the short- and medium-term solid organ transplant (SOT) survival. The use of steroids, mycophenolate mofetil and calcineurin inhibitors (CNI) have led to annual renal graft survival rates exceeding 90% in the last six decades. On the other hand, attrition rates of the allograft beyond the first year have remained unchanged. In addition, there is a persistent high cardiovascular (CV) mortality rate among transplant recipients with functioning grafts. These shortcomings are in part due to the metabolic effects of steroids, CNI and sirolimus (SRL), all of which are implicated in hypertension, new onset diabetes after transplant (NODAT), and dyslipidemia. In a bid to reduce the required amount of harmful maintenance agents, T-cell-depleting antibodies are increasingly used for induction therapy. The downsides to their use are greater incidence of opportunistic viral infections and malignancy. On the other hand, inadequate immunosuppression causes recurrent rejection episodes and therefore early-onset chronic allograft dysfunction. In addition to the adverse metabolic effects of the steroid rescue needed in these settings, the generated proinflammatory milieu may promote accelerated atherosclerotic disorders, thus setting up a vicious cycle. The recent availability of newer agent, belatacept holds a promise in reducing the incidence of metabolic disorders and hopefully its long-term CV consequences. Although therapeutic drug monitoring as applied to CNI may be helpful, pharmacodynamic tools are needed to promote a customized selection of IS agents that offer the most benefit to an individual without jeopardizing the allograft survival.

show abstract

Low-Density Lipoprotein Oxidizability and the Alteration of Its Fatty Acid Content in Renal Transplant Recipients Treated With Cyclosporine/Tacrolimus

Cited by 7 publications

References 25 publications

In vivo oxidized low-density lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study comparing cyclosporine a and tacrolimus based regiments

In vivo oxidized low-density lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study comparing cyclosporine a and tacrolimus based regiments

Dyslipidemia after pediatric renal transplantation—The impact of immunosuppressive regimens

Metabolic consequences of modern immunosuppressive agents in solid organ transplantation

Contact Info

Product

Resources

About